|
Zacks Short Term Rating on Rockwell Medical, Inc. (NASDAQ:RMTI) - News Watch International |
 |
 |
|
As much as 4 analysts have advised buy on Rockwell Medical, Inc. (NASDAQ:RMTI) with an average broker rating of 2. Research Analysts at Zacks has the shares a rating of 3, which implies that the firms recommendation is Neutral on the company. Rockwell Medical, Inc. (NASDAQ:RMTI): 4 Analyst have given the stock of Rockwell Medical, Inc. (NASDAQ:RMTI) a near short term price target of $16.25. The standard deviation reading, which is a measure by which the stock price is expected to swing away from the mean estimate, is at $9.18. The higher price target estimate is at $26 while the lower price estimates are fixed at $4.
The company shares have rallied 26.08% in the past 52 Weeks. On June 16, 2015 The shares registered one year high of $14.95 and one year low was seen on December 15, 2014 at $8.1. The 50-day moving average is $11.47 and the 200 day moving average is recorded at $10.55. S&P 500 has rallied 8.87% during the last 52-weeks. Rockwell Medical, Inc. (NASDAQ:RMTI) rose 3.9% or 0.55 points on Monday and made its way into the gainers of the day. After trading began at $14.35 the stock was seen hitting $14.66 as a peak level and $14.1101 as the lowest level. The stock ended up at $14.65. The daily volume was measured at 693,031 shares. The 52-week high of the share price is $14.95 and the 52-week low is $8.095. The company has a market cap of $735 million.
Rockwell Medical, Inc., formerly Rockwell Medical Technologies, Inc., manufactures hemodialysis concentrate solutions and dialysis kits, and it sells, distributes and delivers these and other ancillary hemodialysis products primarily to hemodialysis providers in the United States, as well as internationally primarily in Asia, Latin America and Europe. Hemodialysis duplicates kidney function in patients with failing kidneys also known as End Stage Renal Disease (ESRD). ESRD is an advanced-stage of chronic kidney disease (CKD) characterized by the irreversible loss of kidney function. Its dialysis solutions (also known as dialysate) are used to maintain life, removing toxins and replacing nutrients in the dialysis patients bloodstream. As of December 31, 2011, it was licensed and was developing renal drug therapies. During the year ended December 31, 2011, it acquired an abbreviated new drug application (ANDA) for a generic version of an intravenous Vitamin-D analogue, calcitriol.
NO COMMENTS
LEAVE A REPLY
|
|
A single RNA molecule links neuroblastoma to renal carcinoma - Biotechin.Asia |
|
|
|
The neuroblastoma-associated transcript 1 (NBAT1), previously known as CASC14, is a long noncoding RNA (lncRNA) molecule that is devoid of producing any functional protein. Initially, NBAT1 was found to have a plausible role in progression of neuroblastoma (NB) tumors, but more recently, a Chinese group from different universities published a paper in International Journal of Clinical and Experimental Pathology showing that NBAT1 is associated with poor prognosis in patients with clear cell renal cell carcinoma (ccRCC).
Although NB and ccRCC develop due to different molecular drivers that disturb normal cellular functions, it looks quite surprising that one RNA molecule maintains the same properties in promoting tumors in both cases. As a matter of fact, NB is a type of cancer that affects the sympathetic nervous system and arises from improper development and differentiation of neural crest cells. It is considered as the third most common tumor affecting infants and comprises around 7% of the total tumors observed in children.
The NB patients are categorized into many types; including patients with low-risk NB tumors and patients with high-risk tumors. The low-risk tumors are not associated with metastasis, rather they tend to differentiate into mature cells and respond to chemotherapy. On the contrary, high-risk tumors usually spread into different parts of the body and they show unfavorable clinical outcome due to their aggressive nature.
On the other hand, renal cell carcinoma (RCC) is responsible for almost 3% of all malignancies in adults, whereas ccRCC represents the major subtype of RCC. Unfortunately, most of RCC patients are administered to surgical treatment at later stages due to improper diagnosis of the complex symptoms; so nearly 30% of the patients develop metastatic tumors leading to lower survival time.
Few months ago, Gaurav Pandey and his colleagues at University of Gothenburg in Sweden published a research article in Cancer Cell journal pointing out to the role of NBAT1 in NB. Using state-of-the-art RNA-Seq technology, Pandey and his colleagues compared the RNA expression levels of high-risk and low-risk tumors derived from patients’ primary tumors. Their analysis indicated that NBAT1tends to be expressed in lower levels in case of high-risk tumors compared to low-risk tumors. Further experiments on animals suggested an essential tumor suppression function of NBAT1. Enforced ectopic expression of NBAT1 induces cellular differentiation and restricts cellular proliferation by epigenetic silencing of common oncogenes. Statistical analysis in two different German and Swedish cohorts correlated lower expression of NBAT1 with lower survival time, while higher expression favors better prognosis.
The joint Chinese group was able to reproduce and verify the same observations in ccRCC patients. Using primary tumors derived from RCC patients, they reported lower expression of NBAT1 in more aggressive ccRCC tumors with advanced pathological features. Moreover, their experiments demonstrated the role of NBAT1 in prohibiting invasion and migration capacity of renal cancer cells. Although the current study in ccRCC has not discussed much about the molecular machinery that relates NBAT1 to other molecules in the cell, the data further confirm the possible use of NBAT1 as an independent prognostic marker to distinguish low-risk tumors from high-risk tumors.
For future perspectives, it would be worth to interrogate the common molecular networks that got affected upon abnormal expression of NBAT1 in NB and ccRCC; so that we can gain a comprehensive insight on molecular events that link diverse types of cancer.
|
|
|
Renal Failure Scare in Ganjam Village - The New Indian Express |
|
|
|
BERHAMPUR: The claims of the Central and State Governments notwithstanding, safe drinking water remains a distant dream for many in Ganjam district. A case in point is Ekagharia village under Jagannathprasad block. In the last three years, nine persons of the village have died due to renal failure caused by consumption of contaminated water. Six others of the village are suffering from renal disorders.
Ekagharia village comes under Alasu gram panchayat and is inhabited by around 34 families, mostly tribals. Although the village has four tubewells, their muddy water is unfit for human consumption. Yet, villagers consume the water in absence of any alternative source. As a result, many of them fall victim to renal disorders.
Alasu Sarpanch Sangita Mohapatra had earlier informed the health officials of the Jagannathprasad Community Health Centre, who had apprised Chief District Medical Officer (CDMO) Mrutyunjaya Mishra. Subsequently, a team of doctors led by Medical Officer Suresh Chandra Samant visited the village and collected water samples from the tubewells. The samples have been sent to the Regional Research Laboratory at Bhubaneswar for test.
Besides, a complaint regarding the water quality from the tubewells was lodged with the Water Supply Department by the Sarpanch after which, three tubewells were sealed. Currently, all the families depend on the one tubewell for their water requirement. But, muddy water comes out of this tubewell also. Some villagers are now collecting water from an open well, on the outskirts of the village, that has not been disinfected since ages.
Samant informed that reports of the water samples have been received and the water is unfit for consumption. “We have decided to examine the bacterial content of the water,” he said.
People of another village in the district have been facing kidney problems as well. In April this year, similar reports were received from Badaputi village.
Apparently, 20 villagers of Badaputi had succumbed to renal failure in the last four years.
|
|
Is anatomic complexity associated with renal tumor growth kinetics under ... - UroToday |
|
|
INTRODUCTION: Linear growth rate (LGR) is the most commonly employed trigger for definitive intervention in patients with renal masses managed with an initial period of active surveillance (AS).
Using our institutional cohort, we explored the association between tumor anatomic complexity at presentation and LGR in patients managed with AS.
METHODS AND MATERIALS: Enhancing renal masses managed expectantly for at least 6 months were included for analysis. The association between Nephrometry Score and LGR was assessed using generalized estimating equations, adjusting for the age, Charlson score, race, sex, and initial tumor size.
RESULTS: Overall, 346 patients (401 masses) met the inclusion criteria (18% ?cT1b), with a median follow-up of 37 months (range: 6-169). Of these, 44% patients showed progression to definitive intervention with a median duration of 27 months (range: 6-130). On comparing patients managed expectantly to those requiring intervention, no difference was seen in median tumor size at presentation (2.2 vs. 2.2cm), whereas significant differences in median age (74 vs. 65y, P< 0.001), Charlson comorbidity score (3 vs. 2, P< 0.001), and average LGR (0.23 vs. 0.49cm/y, P< 0.001) were observed between groups. Following adjustment, for each 1-point increase in Nephrometry Score sum, the average tumor LGR increased by 0.037cm/y (P = 0.002). Of the entire cohort, 6 patients (1.7%) showed progression to metastatic disease.
CONCLUSIONS: The demonstrated association between anatomic tumor complexity at presentation and renal masses of LGR of clinical stage 1 under AS may afford a clinically useful cue to tailor individual patient radiographic surveillance schedules and warrants further evaluation.
Written by:
Mehrazin R, Smaldone MC, Egleston B, Tomaszewski JJ, Concodora CW, Ito TK, Abbosh PH, Chen DY, Kutikov A, Uzzo RG. Are you the author?
Department of Urology & Oncological Science, Icahn School of Medicine at Mount Sinai, New York, NY; Department of Surgical Oncology, Fox Chase Cancer Center-Temple University Health System, Philadelphia, PA; Biostatistics & Bioinformatics Facility, Fox Chase Cancer Center-Temple University Health System, Philadelphia, PA; Department of Surgery, MD Anderson Cancer Center at Cooper, Rowan, University School of Medicine, Camden, NJ; Department of Surgical Oncology, Fox Chase Cancer Center-Temple University Health System, Philadelphia, PA. This email address is being protected from spambots. You need JavaScript enabled to view it.
Reference: Urol Oncol. 2015 Apr;33(4):167.e7-167.e12.
doi: 10.1016/j.urolonc.2015.01.013
PMID: 25778696
UroToday.com Renal Cancer Section
|
|
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
